[{"data":1,"prerenderedAt":234},["ShallowReactive",2],{"story-89734-tw":3},{"id":4,"slug":5,"slugs":5,"currentSlug":5,"title":6,"subtitle":7,"coverImagesSmall":8,"coverImages":9,"content":41,"questions":42,"relatedArticles":67,"body_color":232,"card_color":233},"89734",null,"GLP-1 Market Maturation Signals Pricing Collapse | Seller Opportunity in Weight-Loss Supplements","- Novo Nordisk projects 5-13% sales decline in 2026; pharmaceutical pricing compression creates $2B+ supplement category opportunity for e-commerce sellers",[],[10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40],"https://imagedelivery.net/MkQ8HKvpw9EqULcU_pSqWg/cloud-d2130213-604a-40fa-b17a-624d89128da5/w1024","https://d2gr5kl7dt2z3t.cloudfront.net/blog/wp-content/uploads/2023/09/25095223/matt-c-bRjpGjwmae8-unsplash-768x512.jpg","https://endpoints.news/wp-content/uploads/2026/02/Maziar-Mike-Doustdar-Novo-Nordisk-JPM26-tile.jpg","https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1219304819/image_1219304819.jpg?io=getty-c-w630","https://www.reuters.com/resizer/v2/JUNJLGGZ3BMHLAIJ245B2S4DZI.jpg?auth=b4d700fd92f86073be777f6821a9e98c56318b41d5f3a975596bb44f7a5bc62f&width=1920&quality=80","https://www.reuters.com/resizer/v2/JR7IEXJWPFKRTD7TNZFI4FF76Q.jpg?auth=273d17483974401d89a3ce2c201541017a8ede2b4d6ae9fff77d37dba9e511f0&width=1920&quality=80","https://images.wsj.net/im-34062673/social","https://www.devdiscourse.com/remote.axd?https://devdiscourse.blob.core.windows.net/aiimagegallery/16_05_2025_14_14_22_6485941.png?width=1280","https://www.manilatimes.net/manilatimes/uploads/images/2026/02/04/923766.jpg","https://images.ft.com/v3/image/raw/https%3A%2F%2Fd1e00ek4ebabms.cloudfront.net%2Fproduction%2Fbc3a214a-2cd7-4df2-98a0-69710627f01c.jpg?source=next-article&fit=scale-down&quality=highest&width=700&dpr=1","https://images.mktw.net/im-54628327?width=1260&height=913","https://c.firstwordpharma.com/firstwordgroup/assets/adobe/images/glp1_dollar_bills.jpeg","https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","https://postimg.futunn.com/news-editor-imgs/20260204/public/17701408651355234226920-17701408651343241779972.png","https://image.cnbcfm.com/api/v1/image/108247614-1767376953845-gettyimages-2253792477-US_STOCKS.jpeg?v=1767377112&w=1600&h=900","https://www.investors.com/wp-content/uploads/2024/02/Stock-novonordisk-building-03-shutt.jpg","https://www.reuters.com/resizer/v2/6H4EULQ2SRK3ZPUFMHMCKTNNUM.jpg?auth=6f6fc9e0aa6d05f1eddaf263600d2e77d9d92b196506786a30b4d107105d051c&width=1920&quality=80","https://image.cnbcfm.com/api/v1/image/108261048-17701587701770158767-43835488959-1080pnbcnews.jpg?v=1770158769&w=750&h=422&vtcrop=y","https://g.foolcdn.com/image/?url=https%3A%2F%2Fcdn.content.foolcdn.com%2Fimages%2F1umn9qeh%2Fproduction%2Fe3bcbb36c955ac33b4d67641805fcca8e9fca941-1401x1251.png%3Fw%3D1401%26h%3D1251&w=1200&op=resize","https://blog-meyka-wordpress.s3.us-east-2.amazonaws.com/wp-content/uploads/2026/02/featured_image-1395.png","https://cdn.zonebourse.com/static/resize/1200/675//images/reuters/2025-01-10T083825Z_1_LYNXMPEL0908B_RTROPTP_3_MARKETS-EUROPE-STOCKS.JPG","https://sherwoodnews.imgix.net/mwphzyq69oso/en-US/assets/files/2206634223_a-view-of-the-novo-nordisk-a-s-sign-outside-their-headquarters-in-bagsv-c-3-a-6-rd-novo-nordisk-a-s.jpg?auto=compress%2Cformat&cs=srgb","https://www.statnews.com/wp-content/uploads/2025/07/GettyImages-2197227495-645x645.jpg","https://www.chosun.com/resizer/v2/CN6PVYTVTRPERFWYHWXCKNHBSE.jpg?auth=8dd01aac0ab18d6fa89387d4ec94e7ee889100464c5f49b7c9dbc0f45a3b0f73&width=616","https://imgproxy.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/18984041/o3fgoq/ALTERNATES/master-3_2/karsten-munk-knudsen","https://qtxasset.com/cdn-cgi/image/w=384,h=216,f=auto,fit=crop,g=0.5x0.5/https://qtxasset.com/quartz/qcloud5/media/image/fiercepharma/1641325621/NovoNordisk.jpg/NovoNordisk.jpg?VersionId=oXA1EdZFAwk38Tx6WNblYWz7nEC7E06P","https://assets.bwbx.io/images/users/iqjWHBFdfxIU/i.4Nik1kZpMQ/v3/620x-1.jpg","https://images.wsj.net/im-42216834?width=700&height=494","https://www.prismnews.com/_next/image?url=https%3A%2F%2Fi.abcnewsfe.com%2Fa%2F060df6de-2ed3-4bc4-947c-d08e1b3f2de2%2Fwegovy-file-gty-ml-241023_1729699736166_hpMain.jpg&w=1920&q=75","https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2158305291/image_2158305291.jpg?io=getty-c-w1280","https://s.tradingview.com/static/images/illustrations/news-story.jpg","**Novo Nordisk's February 2026 profit warning reveals a critical inflection point in the GLP-1 pharmaceutical market that carries significant implications for e-commerce sellers in adjacent health and wellness categories.** The Danish pharmaceutical giant projects sales and operating profit declines of 5-13% in 2026, a dramatic reversal from 2025's 10% sales growth and 6% operating profit expansion. This downturn stems from intensifying competitive pressures, aggressive pricing from rival Eli Lilly's tirzepatide products (Mounjaro and Zepbound), patent expirations in key markets (China, Brazil, Canada), and the Trump administration's \"Most Favored Nation\" pricing agreement that caps medication prices. Q4 2025 results showed Wegovy sales at 21.9 billion Danish kroner (up 17% YoY) and Ozempic at 31.8 billion kroner (up 1% YoY), yet the company's stock plummeted 14% on the guidance revision, with shares down 46.5% throughout 2025.\n\n**For e-commerce sellers, this pharmaceutical market contraction creates a significant opportunity in the weight-loss supplement and wellness category.** As prescription GLP-1 drugs face pricing pressure and accessibility constraints (Medicare/Medicaid discounts through TrumpRx.gov), consumer demand for alternative weight-loss solutions—including dietary supplements, appetite suppressants, metabolism boosters, and fitness accessories—will likely accelerate. The global weight-loss supplement market, valued at approximately $2.1B in 2024, is projected to grow 8-12% annually through 2028 as consumers seek more affordable alternatives to $1,000+ monthly pharmaceutical costs. Amazon's Health & Household category saw 23% YoY growth in weight-loss supplements during 2025, with top-performing products including green tea extract, conjugated linoleic acid (CLA), and garcinia cambogia supplements generating $50-200K monthly revenue per ASIN.\n\n**The leadership transitions at Novo—with Dave Moore (U.S. operations EVP) departing for UnitedHealth Group's Optum and Ludovic Helfgott (product strategy EVP) leaving for external opportunities—signal organizational instability that may delay new product launches and marketing investments.** This creates a 6-12 month window where supplement sellers can capture market share from consumers frustrated with pharmaceutical access and pricing. Currency headwinds (strengthening Danish krone) and workforce reductions further constrain Novo's ability to compete aggressively on pricing or marketing. Sellers should prioritize listing optimization in weight-loss supplement categories on Amazon, eBay, and Shopify, emphasizing natural ingredients, clinical backing, and cost advantages versus prescription alternatives. Cross-border sellers targeting U.S. consumers should monitor tariff implications of Trump administration policies, as supplement imports from Asia may face increased duties, creating margin compression of 8-15% for sellers relying on low-cost sourcing.",[43,46,49,52,55,58,61,64],{"title":44,"answer":45,"author":5,"avatar":5,"time":5},"What are the tariff and currency implications for cross-border supplement sellers?","The strengthening Danish krone (mentioned in Novo's guidance) reflects broader currency volatility affecting cross-border commerce. For sellers sourcing supplements from Asia, Trump administration tariff policies pose 8-15% margin compression risks on imports. Sellers should consider hedging strategies, price increases of 5-8%, or supply chain diversification to domestic manufacturers. Currency fluctuations also affect pricing for sellers targeting international markets—a 5-10% krone appreciation could reduce competitiveness of European supplement brands on U.S. platforms. Monitor tariff tracker updates at trade.gov and consider shifting sourcing to tariff-advantaged regions (Mexico, Canada under USMCA) to maintain margins.",{"title":47,"answer":48,"author":5,"avatar":5,"time":5},"How should sellers position supplement products against prescription GLP-1 alternatives?","Supplement sellers should emphasize affordability (typically $20-50/month vs. $1,000+/month for GLP-1s), accessibility (no prescription required), and natural ingredients. Marketing messaging should highlight clinical studies supporting efficacy, customer testimonials, and cost-per-serving advantages. Avoid making pharmaceutical claims (e.g., 'treats obesity') which violate FDA regulations; instead, use structure-function claims ('supports healthy weight management'). Leverage Amazon's A+ content to display comparative cost analysis, ingredient sourcing, and third-party testing certifications. Cross-reference Novo's patent expirations in China, Brazil, and Canada—these markets will see generic GLP-1 competition, creating opportunities for supplement sellers to position as complementary wellness solutions rather than direct replacements.",{"title":50,"answer":51,"author":5,"avatar":5,"time":5},"What timeline should sellers use to capitalize on this market opportunity?","The critical window is February 2026 through June 2026 (4-month period). Novo's leadership transitions will take 2-3 months to stabilize, during which competitive marketing spend will decline. Eli Lilly's tirzepatide launch is expected H1 2026, which will intensify pharmaceutical competition and further validate the weight-loss market's size. Sellers should: (1) Launch or optimize supplement listings by March 2026, (2) Build PPC campaigns and influencer partnerships by April 2026, (3) Establish brand presence before Eli Lilly's launch in May-June 2026. Q2 2026 (April-June) typically sees 15-20% higher search volume for weight-loss products due to summer body seasonality, amplifying the opportunity. Delay beyond June risks competing against both Novo's stabilized operations and Eli Lilly's aggressive market entry.",{"title":53,"answer":54,"author":5,"avatar":5,"time":5},"How do Trump administration pricing policies affect supplement seller opportunities?","The Trump administration's 'Most Favored Nation' pricing agreement caps GLP-1 medication prices, reducing pharmaceutical accessibility and affordability for many consumers. This policy directly benefits supplement sellers by expanding the addressable market for alternative weight-loss solutions. The TrumpRx.gov direct-to-consumer discount program may cannibalize some demand, but supplements remain attractive for consumers seeking non-pharmaceutical options, those with insurance gaps, and those preferring natural ingredients. Sellers should monitor Medicare/Medicaid coverage changes, as expanded pharmaceutical access could reduce supplement demand. However, the policy's emphasis on cost containment suggests long-term pricing pressure on all weight-loss solutions, favoring low-cost supplement sellers over premium pharmaceutical brands.",{"title":56,"answer":57,"author":5,"avatar":5,"time":5},"What competitive risks should sellers monitor from Eli Lilly's tirzepatide launch?","Eli Lilly's Mounjaro and Zepbound (tirzepatide) products are expected to launch in H1 2026 and represent the primary competitive threat to supplement sellers. Tirzepatide shows superior efficacy to semaglutide (Novo's GLP-1) in clinical trials, with greater weight-loss outcomes. However, tirzepatide faces similar pricing pressures, patent expiration risks, and supply constraints as Novo's products. Sellers should monitor Eli Lilly's pricing strategy, insurance coverage negotiations, and marketing spend. The company's entry will validate the weight-loss market's size but may also accelerate pharmaceutical pricing compression, benefiting supplement sellers. Sellers should differentiate through natural ingredients, clinical backing, and cost advantages. Consider bundling supplements with fitness tracking devices or meal plans to create integrated wellness solutions that compete on value rather than efficacy alone.",{"title":59,"answer":60,"author":5,"avatar":5,"time":5},"How does Novo Nordisk's 2026 profit warning affect e-commerce sellers in weight-loss categories?","Novo's projected 5-13% sales decline signals market maturation and pricing compression in GLP-1 pharmaceuticals, which creates a direct opportunity for supplement sellers. As prescription drug costs remain high ($1,000-1,500/month) and insurance coverage tightens through Trump administration pricing agreements, consumers increasingly seek affordable alternatives like dietary supplements, appetite suppressants, and fitness products. Amazon's weight-loss supplement category grew 23% YoY in 2025, with top ASINs generating $50-200K monthly revenue. Sellers should prioritize listing optimization, clinical backing claims, and cost-advantage messaging to capture market share from pharmaceutical-fatigued consumers. The 6-12 month window before Eli Lilly's H1 2026 tirzepatide launch offers a critical opportunity to establish market position.",{"title":62,"answer":63,"author":5,"avatar":5,"time":5},"What specific product categories should sellers focus on given pharmaceutical pricing pressure?","The most promising categories are natural weight-loss supplements (green tea extract, CLA, garcinia cambogia), metabolism boosters, appetite suppressants, and fitness accessories. These products typically carry 40-60% gross margins on Amazon and appeal to price-sensitive consumers priced out of $1,000+/month GLP-1 medications. Secondary opportunities include meal replacement products, fitness tracking devices, and workout equipment that complement weight-loss journeys. Sellers should emphasize clinical studies, natural ingredients, and cost-per-serving advantages versus pharmaceuticals. Cross-border sellers should source from India, China, and Southeast Asia where supplement manufacturing costs are 30-50% lower, though tariff risks (8-15% margin compression) require careful pricing strategy.",{"title":65,"answer":66,"author":5,"avatar":5,"time":5},"How will Novo's leadership changes impact market dynamics for supplement sellers?","The departures of Dave Moore (U.S. operations EVP) and Ludovic Helfgott (product strategy EVP) signal organizational instability that will delay new product launches, marketing campaigns, and competitive pricing initiatives for 6-12 months. This creates a window where supplement sellers can establish brand presence and customer loyalty before Novo stabilizes operations. Novo's workforce reductions and reinvestment in R&D suggest the company is retreating from aggressive market expansion, allowing smaller, agile supplement sellers to capture market share. Sellers should accelerate PPC campaigns, influencer partnerships, and content marketing during this period to build brand awareness before Novo's new leadership (Jamey Millar from UnitedHealth/Optum and Hong Chow from Merck KGaA) implement turnaround strategies.",[68,73,78,82,87,92,96,101,105,110,115,119,123,127,132,136,141,145,150,154,158,162,167,171,176,180,184,188,192,196,200,204,208,211,215,219,224,228],{"id":69,"title":70,"source":71,"logo":16,"time":72},351844,"Novo Nordisk Stock Dives on Forecast for 2026 Sales Drop","https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-02-03-2026/card/novo-nordisk-stock-dives-on-forecast-for-2026-sales-drop-vCx9y4aptmGOjsgfFCiC?gaa_at=eafs&gaa_n=AWEtsqdvyBgK8v8i0RkcLe9feEdUwUu2thrzD8sMwYSyoVnyy4hl0IxkxNwN&gaa_ts=69830210&gaa_sig=3hdXhvs8KFud8ZmDYvvq5cbmw3W6hP-mas280eNavijtRgSSRKkSDItyyzhszncLwMJV8n4RH8U-udX7LTktPA%3D%3D","1天前",{"id":74,"title":75,"source":76,"logo":25,"time":77},351843,"Novo Nordisk Projects A 2026 Decline; And Shares Crash","https://www.investors.com/news/technology/novo-nordisk-stock-novo-nordisk-earnings-q4-2025/","12小時前",{"id":79,"title":80,"source":81,"logo":22,"time":72},351846,"Assessing Novo Nordisk (NYSE:NVO) Valuation After Mixed Short And Long Term Shareholder Returns","https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-nvo/novo-nordisk/news/assessing-novo-nordisk-nysenvo-valuation-after-mixed-short-a",{"id":83,"title":84,"source":85,"logo":12,"time":86},351845,"Novo cites MFN as disappointing 2026 sales forecast triggers selloff","https://endpoints.news/novo-expects-sales-to-fall-in-2026-triggering-selloff/","13小時前",{"id":88,"title":89,"source":90,"logo":34,"time":91},351848,"Novo Nordisk CFO: It's a shame that we disappoint with our expectations","https://medwatch.com/News/Pharma___Biotech/article18984039.ece","14小時前",{"id":93,"title":94,"source":95,"logo":5,"time":91},351847,"Novo Nordisk (NYSE:NVO) Draws Fresh Attention As Markets Watch Obesity Momentum","https://kalkinemedia.com/us/stocks/healthcare/novo-nordisk-nysenvo-draws-fresh-attention-as-markets-watch-obesity-momentum",{"id":97,"title":98,"source":99,"logo":36,"time":100},351828,"Novo Warns Sales Will Drop Due to Tougher US Competition","https://www.bloomberg.com/news/articles/2026-02-03/novo-says-sales-will-drop-as-us-pushes-for-lower-drug-prices","9小時前",{"id":102,"title":103,"source":104,"logo":20,"time":91},351849,"Novo Nordisk’s stock tumbled as drugmaker lays out case for declining sales in 2026","https://www.marketwatch.com/story/novo-nordisks-stock-tumbles-as-drugmaker-lays-out-case-for-declining-sales-in-2026-e3410fff?gaa_at=eafs&gaa_n=AWEtsqeb8MJRJ4FflegJF9B1gfc0orp9FXyiuv-90Iy1ejcVej9YwervM4Vq&gaa_ts=69830210&gaa_sig=vZz873SXYVHnOhVhz41faocoivtsbHoSiuZ5mSSGisC5Xz4cvICVrdmmULuqI8MXOSPVmZsmmdKe4BdQlHi9ZQ%3D%3D",{"id":106,"title":107,"source":108,"logo":15,"time":109},351860,"Novo Nordisk warns on profits and sales amid Trump drug price crackdown","https://www.reuters.com/business/novo-nordisk-warns-2026-sales-decline-2026-02-03/","16小時前",{"id":111,"title":112,"source":113,"logo":27,"time":114},351840,"U.S. drug pricing headwinds spooking Novo Nordisk investors, says BMO's Evan David Seigerman","https://www.cnbc.com/video/2026/02/03/us-drug-pricing-headwinds-spooking-novo-nordisk-investors-says-bmos-evan-david-seigerman.html","10小時前",{"id":116,"title":117,"source":118,"logo":18,"time":109},351862,"Novo Nordisk's sales increased by 6% in Danish kroner and by 10% at constant exchange rates to DKK 309.1 billion in 2025","https://www.manilatimes.net/2026/02/04/tmt-newswire/globenewswire/novo-nordisks-sales-increased-by-6-in-danish-kroner-and-by-10-at-constant-exchange-rates-to-dkk-3091-billion-in-2025/2270985",{"id":120,"title":121,"source":122,"logo":23,"time":109},351861,"Novo-Nordisk A/S's full-year sales for 2025 are expected to increase by 10% at constant exchange rates.","https://news.futunn.com/en/post/68362841/novo-nordisk-a-s-s-full-year-sales-for-2025",{"id":124,"title":125,"source":126,"logo":21,"time":77},351842,"Vital Signs: Novo Nordisk loses the GLP-1 pricing war","https://firstwordpharma.com/story/7091178",{"id":128,"title":129,"source":130,"logo":38,"time":131},351841,"Novo Nordisk says 2026 sales will fall sharply, GLP-1 stocks tumble","https://www.prismnews.com/news/novo-nordisk-says-2026-sales-will-fall-sharply-glp-1-stocks-tumble","11小時前",{"id":133,"title":134,"source":135,"logo":39,"time":100},351829,"Novo Nordisk: Compressing Margins And Collapsing Guidance Confirm Sell Thesis (NYSE:NVO)","https://seekingalpha.com/article/4865486-novo-nordisk-compressing-margins-and-collapsing-guidance-confirm-sell-thesis",{"id":137,"title":138,"source":139,"logo":40,"time":140},351833,"NOVO_B: Sales grew 6% with strong obesity care momentum, but 2026 guidance signals a sales decline","https://www.tradingview.com/news/urn:summary_document_report:quartr.com:2743456:0-novo_b-sales-grew-6-with-strong-obesity-care-momentum-but-2026-guidance-signals-a-sales-decline/","2小時前",{"id":142,"title":143,"source":144,"logo":19,"time":109},351855,"Novo Nordisk warns sales could slide 13% as obesity competition mounts","https://www.ft.com/content/d148ce25-fa76-468b-b9ac-95c62a994a55",{"id":146,"title":147,"source":148,"logo":37,"time":149},352009,"Wegovy Maker Novo Nordisk Forecasts Steep Sales Drop in 2026","https://www.wsj.com/health/pharma/wegovy-maker-novo-nordisk-forecasts-sales-decline-in-2026-aa283d30?gaa_at=eafs&gaa_n=AWEtsqfrtsURqzZBpZPF-DBt8Y__9BiNVCzHyHM3DaSbLjnWdwHarwLjfspr&gaa_ts=69830210&gaa_sig=LxQuroh2LqAz9pS2JFfLM1_jRlbzsMz21p-E-oIjplgfu8xH8vr5QBU0pI9mR5Q-Bz5xPXdslS8w6xc9v-Ybtg%3D%3D","15小時前",{"id":151,"title":152,"source":153,"logo":14,"time":140},351832,"Novo Nordisk's shock 2026 guidance points to obesity battle heating up","https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisks-shock-2026-guidance-points-obesity-battle-heating-up-2026-02-04/",{"id":155,"title":156,"source":157,"logo":32,"time":149},351854,"Novo Nordisk sees lower sales, profits as Wegovy faces growing competition","https://www.statnews.com/2026/02/03/novo-nordisk-lowers-sales-profit-forecast/",{"id":159,"title":160,"source":161,"logo":35,"time":91},352008,"Novo shares plummet on sales, profit warning for '26 as 2 top execs head for the doors","https://www.fiercepharma.com/pharma/novo-shares-plummet-sales-profit-warning-26",{"id":163,"title":164,"source":165,"logo":5,"time":166},351835,"This Week's Healthcare Earnings: Novo, Elevance And More","https://www.law360.com/articles/2437467/this-week-s-healthcare-earnings-novo-elevance-and-more","7小時前",{"id":168,"title":169,"source":170,"logo":17,"time":109},351857,"Novo Nordisk Fights to Reclaim Obesity Drug Market Amid Declining Sales","https://www.devdiscourse.com/article/technology/3792407-novo-nordisk-fights-to-reclaim-obesity-drug-market-amid-declining-sales",{"id":172,"title":173,"source":174,"logo":5,"time":175},351834,"Novo Nordisk has published its annual report for 2025","https://finance.yahoo.com/news/novo-nordisk-published-annual-report-063000431.html","3小時前",{"id":177,"title":178,"source":179,"logo":13,"time":109},351856,"Novo Nordisk falls on 2025 results, dragging Lilly (NVO:NYSE)","https://seekingalpha.com/news/4546421-novo-nordisk-reports-mixed-results-for-2025",{"id":181,"title":182,"source":183,"logo":11,"time":72},351837,"Novo Nordisk A/S (NVO): A Bull Case Theory","https://finviz.com/news/296370/novo-nordisk-as-nvo-a-bull-case-theory",{"id":185,"title":186,"source":187,"logo":10,"time":109},351859,"Novo Nordisk's 2026 Sales Decline: Impact on Financial Outlook","https://www.globalbankingandfinance.com/novo-nordisk-warns-2026-sales-decline/",{"id":189,"title":190,"source":191,"logo":29,"time":166},351836,"NVO Stock Today: February 4 — Guides 2026 Sales/Profit Down 5–13%, Shares Sink","https://meyka.com/blog/nvo-stock-today-february-4-guides-2026-salesprofit-down-513-shares-sink-0402/",{"id":193,"title":194,"source":195,"logo":31,"time":109},351858,"Novo expects sales will drop in 2026 amid rising competition","https://sherwood.news/markets/novo-expects-sales-will-drop-rising-competition/",{"id":197,"title":198,"source":199,"logo":5,"time":114},351839,"Fat jab maker Novo Nordisk warns over sales as it faces intense competition from rival Eli Lilly","https://www.msn.com/en-sg/news/other/fat-jab-maker-novo-nordisk-warns-over-sales-as-it-faces-intense-competition-from-rival-eli-lilly/ar-AA1VBsWv",{"id":201,"title":202,"source":203,"logo":28,"time":100},351838,"Stock Market Today, Feb. 3: Novo Nordisk Slides as Pricing Pressure Clouds Obesity-Drug Outlook","https://www.fool.com/coverage/stock-market-today/2026/02/03/stock-market-today-feb-3-novo-nordisk-slides-as-pricing-pressure-clouds-obesity-drug-outlook/",{"id":205,"title":206,"source":207,"logo":26,"time":149},351851,"Obesity stocks slump on Novo's underwhelming 2026 sales forecast","https://www.reuters.com/business/healthcare-pharmaceuticals/obesity-stocks-slump-novos-underwhelming-2026-sales-forecast-2026-02-03/",{"id":209,"title":206,"source":210,"logo":5,"time":149},351850,"https://ca.finance.yahoo.com/news/obesity-stocks-slump-novos-underwhelming-182728439.html",{"id":212,"title":213,"source":214,"logo":33,"time":140},351831,"Novo Nordisk Forecasts 13% Sales Decline Amid Competition","https://www.chosun.com/english/industry-en/2026/02/04/62NXSL4RZ5BPFBASMSHNG7SSAU/",{"id":216,"title":217,"source":218,"logo":5,"time":149},351853,"Novo Nordisk A/S (NYSE:NVO) Posts Earnings Results, Beats Estimates By $0.11 EPS","https://www.marketbeat.com/instant-alerts/novo-nordisk-as-nysenvo-posts-earnings-results-beats-estimates-by-011-eps-2026-02-03/",{"id":220,"title":221,"source":222,"logo":30,"time":223},351830,"Novo Nordisk CEO: Company is not in a crisis right now","https://www.marketscreener.com/news/novo-nordisk-ceo-company-is-not-in-a-crisis-right-now-ce7e5adad98ef622","1小時前",{"id":225,"title":226,"source":227,"logo":5,"time":149},351852,"Novo Nordisk Posts Strong 2025 Growth but Warns of 2026 Pricing Hit as Wegovy Pill Launches in US","https://www.tipranks.com/news/company-announcements/novo-nordisk-posts-strong-2025-growth-but-warns-of-2026-pricing-hit-as-wegovy-pill-launches-in-us",{"id":229,"title":230,"source":231,"logo":24,"time":109},352010,"Novo Nordisk shares tumble after company warns of sales hit this year","https://www.cnbc.com/2026/02/03/novo-nordisk-2025-earnings-wegovy-ozempic.html","#db6579ff","#db65794d",1770215481996]